{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Transplant-related mortality (TRM) defined as any mortality after transplantation except mortality from relapsed disease - Reported as a simple percentage.","groups":[{"description":"CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.\n\nGRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.\n\nTRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0.\n\nrituximab: Given IV\n\nmycophenolate mofetil: Given IV or PO\n\ntacrolimus: Given IV\n\nanti-thymocyte globulin: Given IV\n\nallogeneic hematopoietic stem cell transplantation\n\nlaboratory biomarker analysis: Correlative studies\n\ngraft versus host disease prophyla","id":"OG000","title":"Treatment (Rituximab and Allogeneic HCT Transplant)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At day 100","title":"Transplant-related Mortality (TRM)","type":"SECONDARY","unitOfMeasure":"Participants"}